Trials / Completed
CompletedNCT03854552
A Study in Healthy Men Tests How Different Doses of BI 764198 Are Taken up in the Body and How Well They Are Tolerated.
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 764198 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled, Parallel Group Design)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The main objective of this trial is to investigate safety and tolerability of BI 764198 in healthy male subjects following oral administration of single rising doses. Secondary objectives are the exploration of pharmacokinetics (PK) including dose proportionality of BI 764198 after single oral dosing.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 764198 | capsule |
| DRUG | Placebo | capsule |
Timeline
- Start date
- 2019-03-15
- Primary completion
- 2019-08-07
- Completion
- 2019-08-07
- First posted
- 2019-02-26
- Last updated
- 2021-11-08
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03854552. Inclusion in this directory is not an endorsement.